Interpace Biosciences, Inc. (OTCMKTS:IDXG) Sees Significant Increase in Short Interest

Interpace Biosciences, Inc. (OTCMKTS:IDXG) saw a significant growth in short interest in June. As of June 15th, there was short interest totaling 785 shares, a growth of 7,750.0% from the May 31st total of 10 shares. Based on an average trading volume of 11,418 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Interpace Biosciences Price Performance

Shares of IDXG traded down $0.06 during midday trading on Thursday, reaching $1.64. 26,686 shares of the stock were exchanged, compared to its average volume of 7,976. Interpace Biosciences has a twelve month low of $0.70 and a twelve month high of $2.40. The company has a market capitalization of $7.27 million, a price-to-earnings ratio of -32.80 and a beta of 0.59. The business’s 50-day moving average price is $1.83 and its 200 day moving average price is $1.69.

Interpace Biosciences (OTCMKTS:IDXG) last announced its earnings results on Tuesday, May 12th. The business services provider reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $9.03 million during the quarter. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.